Literature DB >> 36254536

CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment.

Fatima Akram1, Ikram Ul Haq1,2, Sania Sahreen1, Narmeen Nasir1, Waqas Naseem1, Memoona Imitaz1, Amna Aqeel1.   

Abstract

Cancer is a genetic disease stemming from genetic and epigenetic mutations and is the second most common cause of death across the globe. Clustered regularly interspaced short palindromic repeats (CRISPR) is an emerging gene-editing tool, acting as a defense system in bacteria and archaea. CRISPR/Cas9 technology holds immense potential in cancer diagnosis and treatment and has been utilized to develop cancer disease models such as medulloblastoma and glioblastoma mice models. In diagnostics, CRISPR can be used to quickly and efficiently detect genes involved in various cancer development, proliferation, metastasis, and drug resistance. CRISPR/Cas9 mediated cancer immunotherapy is a well-known treatment option after surgery, chemotherapy, and radiation therapy. It has marked a turning point in cancer treatment. However, despite its advantages and tremendous potential, there are many challenges such as off-target effects, editing efficiency of CRISPR/Cas9, efficient delivery of CRISPR/Cas9 components into the target cells and tissues, and low efficiency of HDR, which are some of the main issues and need further research and development for completely clinical application of this novel gene editing tool. Here, we present a CRISPR/Cas9 mediated cancer treatment method, its role and applications in various cancer treatments, its challenges, and possible solution to counter these challenges.

Entities:  

Keywords:  CRISPR/Cas9; cancer; diagnosis; gene editing; immunotherapy

Mesh:

Year:  2022        PMID: 36254536      PMCID: PMC9580090          DOI: 10.1177/15330338221132078

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  159 in total

Review 1.  Genome engineering with zinc-finger nucleases.

Authors:  Dana Carroll
Journal:  Genetics       Date:  2011-08       Impact factor: 4.562

2.  E-CRISP: fast CRISPR target site identification.

Authors:  Florian Heigwer; Grainne Kerr; Michael Boutros
Journal:  Nat Methods       Date:  2014-02       Impact factor: 28.547

3.  Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.

Authors:  Justin Eyquem; Jorge Mansilla-Soto; Theodoros Giavridis; Sjoukje J C van der Stegen; Mohamad Hamieh; Kristen M Cunanan; Ashlesha Odak; Mithat Gönen; Michel Sadelain
Journal:  Nature       Date:  2017-02-22       Impact factor: 49.962

Review 4.  Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics.

Authors:  Wenyi Liu; Luoxi Li; Jianxin Jiang; Min Wu; Ping Lin
Journal:  Precis Clin Med       Date:  2021-07-10

5.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

6.  Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.

Authors:  Ke-Jing Tang; Jerfiz D Constanzo; Niranjan Venkateswaran; Margherita Melegari; Mariya Ilcheva; Julio C Morales; Ferdinandos Skoulidis; John V Heymach; David A Boothman; Pier Paolo Scaglioni
Journal:  Clin Cancer Res       Date:  2016-05-24       Impact factor: 12.531

7.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

8.  Efficient genome editing in zebrafish using a CRISPR-Cas system.

Authors:  Woong Y Hwang; Yanfang Fu; Deepak Reyon; Morgan L Maeder; Shengdar Q Tsai; Jeffry D Sander; Randall T Peterson; J-R Joanna Yeh; J Keith Joung
Journal:  Nat Biotechnol       Date:  2013-01-29       Impact factor: 54.908

9.  MiR-152 suppresses the proliferation and invasion of NSCLC cells by inhibiting FGF2.

Authors:  Zhenshun Cheng; Rongli Ma; Weijun Tan; Li Zhang
Journal:  Exp Mol Med       Date:  2014-09-05       Impact factor: 8.718

Review 10.  Engineering and Design of Chimeric Antigen Receptors.

Authors:  Sonia Guedan; Hugo Calderon; Avery D Posey; Marcela V Maus
Journal:  Mol Ther Methods Clin Dev       Date:  2018-12-31       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.